Intraocular Distribution and Kinetics of Intravitreally Injected Antibodies and Nanoparticles in Rabbit Eyes

Cited 15 time in webofscience Cited 7 time in scopus
  • Hit : 269
  • Download : 217
DC FieldValueLanguage
dc.contributor.authorKim, Hyeong Minko
dc.contributor.authorHa, Seungminko
dc.contributor.authorHong, Hye Kyoungko
dc.contributor.authorHwang, Yoonhako
dc.contributor.authorKim, Pilhanko
dc.contributor.authorYang, Eunsolko
dc.contributor.authorChung, Jae Yongko
dc.contributor.authorPark, Sunyoungko
dc.contributor.authorPark, Young Jooko
dc.contributor.authorPark, Kyu Hyungko
dc.contributor.authorKim, Hyuncheolko
dc.contributor.authorWoo, Se Joonko
dc.date.accessioned2021-01-08T01:50:05Z-
dc.date.available2021-01-08T01:50:05Z-
dc.date.created2020-11-05-
dc.date.created2020-11-05-
dc.date.issued2020-05-
dc.identifier.citationTRANSLATIONAL VISION SCIENCE & TECHNOLOGY, v.9, no.6, pp.1 - 11-
dc.identifier.issn2164-2591-
dc.identifier.urihttp://hdl.handle.net/10203/279740-
dc.description.abstractPurpose: To investigate the intraocular distribution and kinetics of antibodies and nanoparticles in the experimental model. Methods: Antibodies (whole IgG 149kDa, antigen-binding fragments 48.39 kDa) and four kinds of nondegradable nanoparticles (25, 50, 200, and 250 nm) were intravitreally injected in the right eye of New Zealand white rabbits. The average optical density and concentration were used to measure intraocular distribution and kinetics. Results: After intravitreal injection, antibodies were distributed throughout the vitreous humor and eliminated gradually into anterior and posterior routes. Fluorescence intensity decreased 1 day after injection and was not detected 25 days after injection. The nondegradable nanoparticles migrated posteriorly to the retina 7 days after injection onward and anteriorly to the aqueous humor from 1 hour to 1 day after injection. The fluorescence intensity of the nanoparticles was relatively stable in the vitreous humor, compared to antibodies. Nanoparticles accumulated on the internal limiting membrane of the retina with no penetration into deeper retinal tissue, whereas the smaller size 25 nm nanoparticles passed across the ciliary body and moved into choroid, retina, and suprachoroidal space. A gradual decrease of nanoparticles by their sizes in the vitreous after 30 days after injection was described as the percentage ratio: 61.1% (25 nm), 69.1% (50 nm), 78.6% (200nm), and 85.3% (250 nm). Conclusions: Our study revealed the in vivo intraocular distribution and kinetics of antibodies and nanoparticles with diverse sizes and the result might help to develop newer intraocular drugs and drug delivery systems to treat retinal diseases. Translational Relevance: These experimental results can be valuable data for human research.-
dc.languageEnglish-
dc.publisherASSOC RESEARCH VISION OPHTHALMOLOGY INC-
dc.titleIntraocular Distribution and Kinetics of Intravitreally Injected Antibodies and Nanoparticles in Rabbit Eyes-
dc.typeArticle-
dc.identifier.wosid000617723100002-
dc.identifier.scopusid2-s2.0-85088965991-
dc.type.rimsART-
dc.citation.volume9-
dc.citation.issue6-
dc.citation.beginningpage1-
dc.citation.endingpage11-
dc.citation.publicationnameTRANSLATIONAL VISION SCIENCE & TECHNOLOGY-
dc.identifier.doi10.1167/tvst.9.6.20-
dc.contributor.localauthorKim, Pilhan-
dc.contributor.nonIdAuthorKim, Hyeong Min-
dc.contributor.nonIdAuthorHa, Seungmin-
dc.contributor.nonIdAuthorHong, Hye Kyoung-
dc.contributor.nonIdAuthorYang, Eunsol-
dc.contributor.nonIdAuthorChung, Jae Yong-
dc.contributor.nonIdAuthorPark, Sunyoung-
dc.contributor.nonIdAuthorPark, Young Joo-
dc.contributor.nonIdAuthorPark, Kyu Hyung-
dc.contributor.nonIdAuthorKim, Hyuncheol-
dc.contributor.nonIdAuthorWoo, Se Joon-
dc.description.isOpenAccessY-
dc.type.journalArticleArticle-
dc.subject.keywordAuthordistribution-
dc.subject.keywordAuthorintraocular-
dc.subject.keywordAuthorintravitreal-
dc.subject.keywordAuthorkinetics-
dc.subject.keywordAuthornanoparticles-
dc.subject.keywordPlusOCCLUSION 12-MONTH OUTCOMES-
dc.subject.keywordPlusSUSTAINED BENEFITS-
dc.subject.keywordPlusPHARMACOKINETICS-
dc.subject.keywordPlusRANIBIZUMAB-
dc.subject.keywordPlusBEVACIZUMAB-
dc.subject.keywordPlusDELIVERY-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordPlusFRAGMENT-
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 15 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0